Abstract
Recurrence risk stratification of patients undergoing primary surgical resection for hepatocellular carcinoma (HCC) is an area of active investigation, and several staging systems have been proposed to optimize treatment strategies. However, as many as 70% of patients still have tumor recurrence at 5 years post-surgery. Routine hematoxylin and eosin (H&E)-stained histopathology slides may contain morphologic features associated with tumor recurrence. In this study, we developed and independently validated a deep learning-based system (HCC-SurvNet) that provides risk scores for disease recurrence after primary surgical resection, directly from H&E-stained digital whole-slide images of formalin-fixed, paraffin embedded liver resections. Our model achieved a concordance index of 0.724 on a held-out internal test set of 53 patients, and 0.683 on an external test set of 198 patients, exceeding the performance of standard staging using the American Joint Committee on Cancer (AJCC)/International Union against Cancer (UICC) Tumor-Node-Metastasis (TNM) classification system, on both the internal and external test cohorts (p = 0.018 and 0.025, respectively). We observed statistically significant differences in the survival distributions between low- and high-risk subgroups, as stratified by the risk scores predicted by HCC-SurvNet on both the internal and external test sets (log-rank p-value: 0.0013 and < 0.0001, respectively). On multivariable Cox proportional hazards analysis, the risk score was an independent risk factor for post-surgical recurrence, on both the internal (hazard ratio (HR) = 7.44 (95% CI: 1.60, 34.6), p = 0.0105) and external (HR = 2.37 (95% CI: 1.27, 4.43), p = 0.0069) test sets. Our results suggest that deep learning-based models can provide recurrence risk scores which may augment current patient stratification methods, and help refine the clinical management of patients undergoing primary surgical resection for HCC.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
No external funding was received for the work in this manuscript.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Stanford University IRB
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All whole-slide-images for the TCGA cohort are publicly available at https://portal.gdc.cancer.gov/. The Stanford whole-slide images are not publicly available, in accordance with institutional requirements governing human subject privacy protection.
